Cardiac Involvement in Patients With Duchenne/Becker Muscular Dystrophy

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02470962

Enrollment

Registered

2015-06-12

Start date

2015-06-01

Completion date

2022-03-22

Last updated

2025-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Duchenne / Becker Muscular Dystrophy

Brief summary

This study evaluates the function of the heart in young patients with muscular dystrophy type Duchenne or Becker. Participants have their hearts examined at regular intervals by ultrasound (echocardiography) and cardiac magnetic resonance imaging.

Detailed description

Muscular dystrophy leads to progressive loss of function in all muscles during childhood and adolescence, including the heart. The usual method to evaluate the heart is echocardiography, emphasizing few parameters. Cardiac magnetic resonance imaging is not as widely available as echocardiography, but early changes can be detected before they become visible on echocardiography. In this study, the investigators compare the methods of measuring heart function in order to find the best measurements for follow up and to see how fast the degenerative changes occur in the hearts of patients with muscular dystrophy.

Interventions

OTHERObservation

Observation by serial echocardiography with extended techniques and cardiac magnetic resonance imaging

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

8 Years to 18 Years

Healthy volunteers

Yes

Inclusion criteria

* Boys aged 8 to 18 years with DMD/BMD confirmed genetically or by muscle biopsy * Informed consent

Exclusion criteria

* Other clinically significant concomitant disease states (e.g., renal failure) * Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant or his/her parents or legal caregivers, * Inability to lie still for the duration of the imaging procedures (approximately 45 minutes each for echocardiography and CMR) * MR-incompatible implanted or accidentally incorporated metal device or claustrophobia that prohibits use of magnetic resonance imaging

Design outcomes

Primary

Measure	Time frame
Left ventricular ejection fraction	3 years per patient

Secondary

Measure	Time frame
Quantification of fibrosis by LGE/T1 mapping	3 years per patient
NT-proBNP	3 years per patient

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026